Roles of E-cadherin and cyclooxygenase enzymes in predicting different survival patterns of optimally cytoreduced serous ovarian cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5715-5719

  Taşkin, Salih ^a   Dünder, Ilkkan ^a   Erol, Ebru ^a   Taşkin, Elif Aylin ^a   Kiremitçi, Saba ^a   Öztuna, Derya ^b   Sertçelik, Ayşe ^a  

^a Department of Obstetrics and Gynecology ^*  (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Cyclooxygenase; E cadherin; Ovarian cancer; Survival

Indexed keywords

EID: 84874071970     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5715     Document Type: Article

References (35)

1. Ali-Fehmi R, Morris RT, Bandyopadhyay S, et al (2005). Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol, 192, 819-25.
2. Brouxhon S, Kyrkanides S, O'Banion MK, et al (2007). Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism. Cancer Res, 15, 7654-64.
3. Blechschmidt K, Sassen S, Schmalfeldt B, et al (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer, 98, 489-95.
4. Chi DS, Liao JB, Leon LF, et al (2001). Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol, 82, 532-7.
5. Chen Q, Shinohara N, Abe T, et al (2004). Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J Urol, 172, 2153-7.
6. Chang YW, Marlin JW, Chance TW, et al (2006). RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res, 66. 11700-8.
7. Cho EY, Choi Y, Chae SW, et al (2006). Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int, 56, 62-70.
8. Denkert C, Kobel M, Pest S, et al (2002). Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol, 160, 893-903.
9. Dohadwala M, Yang SC, Luo J, et al (2006). Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res, 66, 5338-45.
10. Erkinheimo TL, Lassus H, Finne P, et al (2004). Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER 2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res, 10, 538-45.
11. Gupta RA, Tejada LV, Tong BJ, et al (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res, 63, 906-11.
12. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al (2004). Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol, 15, 1535-42.
13. Harris RE, Beebe-Donk J, Doss H, et al (2005). Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs in cancer prevention: a critical review of nonselective COX-2 blockade. Oncol Rep, 13, 559-83.
14. Huang KJ, Sui LH (2012). The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol, 29, 318-23.
15. Imai T, Horiuchi A, Wang C, et al (2003). Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol, 163, 1437-47.
16. Jin HY, Feng YJ (2005). Inhibitory effects of antisense Snail on invasion and migration of ovarian carcinoma cells. Zhong Hua Fu Chan Ke Za Zhi, 40, 400-3.
17. Jang TJ, Jeon KH, Jung KH (2009). Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. Yonsei Med J, 50, 818-24.
18. Jin H, Yu Y, Zhangs T, et al (2010). Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer, 126, 2102-11.
19. Jang TJ, Cha WH, Lee KS (2010). Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch, 457, 319-28.
20. Lee JS, Choi YD, Lee JH, et al (2006). Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer, 16, 247-53.
21. Li W, Wang J, Jiang HR, et al (2011). Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo. Int J Mol Sci, 12, 668-81.
22. Makarla PB, Saboorian MH, Ashfaq R, et al (2005). Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res, 11, 5365-9.
23. Menczer J (2009). Cox-2 expression in ovarian malignancies: A review of the clinical aspects. Eur J Obstet Gynecol Reprod Biol, 146, 129-32.
24. Moody TW, Switzer C, Santana-Flores W, et al (2010). Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer, 68, 154-60.
25. Okamoto A, Shirakawa T, Bito T, et al (2008). Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 71, 156-60.
26. Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-31.
27. Rao DS, Gui D, Koski ME, et al (2006). An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol, 14, 375-83.
28. Sun WH, Zhu F, Chen GS, et al (2008). Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Lett, 263, 302-11.
29. Shim HS, Yoon BS, Cho NH (2009). Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol, 40, 693-8.
30. Uddin S, Ahmed M, Hussain A, et al (2010). Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer, 126, 382-94.
31. Voutilainen KA, Anttila MA, Sillanpää SM, et al (2006). Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol, 59, 460-7.
32. Yuecheng Y, Hongmei L, Xiaoyan X (2006). Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis, 23, 65-74.
33. Yoshida J, Horiuchi A, Kikuchi N, et al (2009). Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol, 42, 82-91.
34. Wang Y, Sheng Q, Spillman MA, et al (2012). Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene, 31, 2512-20.
35. Zhou Y, Ran J, Tang C, et al (2007). Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther, 6, 269-75.